BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He L, Tzarum N, Lin X, Shapero B, Sou C, Mann CJ, Stano A, Zhang L, Nagy K, Giang E, Law M, Wilson IA, Zhu J. Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. Sci Adv 2020;6:eaaz6225. [PMID: 32494617 DOI: 10.1126/sciadv.aaz6225] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Belz TF, Olson ME, Giang E, Law M, Janda KD. Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model. ACS Med Chem Lett 2020;11:2428-32. [PMID: 33335664 DOI: 10.1021/acsmedchemlett.0c00413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Andrianov AK, Fuerst TR. Immunopotentiating and Delivery Systems for HCV Vaccines. Viruses 2021;13:981. [PMID: 34070543 DOI: 10.3390/v13060981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 [DOI: 10.1101/2020.08.22.262634] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Zhang YN, Paynter J, Sou C, Fourfouris T, Wang Y, Abraham C, Ngo T, Zhang Y, He L, Zhu J. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. bioRxiv 2021:2021. [PMID: 33791704 DOI: 10.1101/2021.03.26.437274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Jackman JA, Yoon BK, Ouyang L, Wang N, Ferhan AR, Kim J, Majima T, Cho N. Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines. Adv Funct Mater 2021;31:2008352. [DOI: 10.1002/adfm.202008352] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
6 Tzarum N, Giang E, Kadam RU, Chen F, Nagy K, Augestad EH, Velázquez-Moctezuma R, Keck ZY, Hua Y, Stanfield RL, Dreux M, Prentoe J, Foung SKH, Bukh J, Wilson IA, Law M. An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Sci Adv 2020;6:eabb5642. [PMID: 32754640 DOI: 10.1126/sciadv.abb5642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
7 Chen F, Tzarum N, Lin X, Giang E, Velázquez-Moctezuma R, Augestad EH, Nagy K, He L, Hernandez M, Fouch ME, Grinyó A, Chavez D, Doranz BJ, Prentoe J, Stanfield RL, Lanford R, Bukh J, Wilson IA, Zhu J, Law M. Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity 2021;54:781-796.e4. [PMID: 33675683 DOI: 10.1016/j.immuni.2021.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
8 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]
9 Tortella GR, Rubilar O, Diez MC, Padrão J, Zille A, Pieretti JC, Seabra AB. Advanced Material Against Human (Including Covid-19) and Plant Viruses: Nanoparticles As a Feasible Strategy. Glob Chall 2020;:2000049. [PMID: 33614127 DOI: 10.1002/gch2.202000049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bukh J. Vaccines against hepatitis C: a travel into neutralisation space. Gut 2021;70:1609-10. [PMID: 33495269 DOI: 10.1136/gutjnl-2020-323377] [Reference Citation Analysis]
11 [DOI: 10.1101/2020.12.02.408328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Brisse M, Vrba SM, Kirk N, Liang Y, Ly H. Emerging Concepts and Technologies in Vaccine Development. Front Immunol 2020;11:583077. [PMID: 33101309 DOI: 10.3389/fimmu.2020.583077] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
13 He L, Chaudhary A, Lin X, Sou C, Alkutkar T, Kumar S, Ngo T, Kosviner E, Ozorowski G, Stanfield RL, Ward AB, Wilson IA, Zhu J. Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. Nat Commun 2021;12:2633. [PMID: 33976149 DOI: 10.1038/s41467-021-22867-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang YN, Paynter J, Sou C, Fourfouris T, Wang Y, Abraham C, Ngo T, Zhang Y, He L, Zhu J. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Sci Adv 2021;7:eabj3107. [PMID: 34669468 DOI: 10.1126/sciadv.abj3107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rodrigues MQ, Alves PM, Roldão A. Functionalizing Ferritin Nanoparticles for Vaccine Development. Pharmaceutics 2021;13:1621. [PMID: 34683914 DOI: 10.3390/pharmaceutics13101621] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wen GP, He L, Tang ZM, Wang SL, Zhang X, Chen YZ, Lin X, Liu C, Chen JX, Ying D, Chen ZH, Wang YB, Luo WX, Huang SJ, Li SW, Zhang J, Zheng ZZ, Zhu J, Xia NS. Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nat Commun 2020;11:3971. [PMID: 32769993 DOI: 10.1038/s41467-020-17737-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Kumar S, Lin X, Ngo T, Shapero B, Sou C, Allen JD, Copps J, Zhang L, Ozorowski G, He L, Crispin M, Ward AB, Wilson IA, Zhu J. Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles. mBio 2021;12:e0042921. [PMID: 34156262 DOI: 10.1128/mBio.00429-21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Marín MQ, Sliepen K, García-Arriaza J, Koekkoek SM, Pérez P, Sorzano CÓS, Gómez CE, Sanders RW, Esteban M. Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV. Vaccines (Basel) 2020;8:E440. [PMID: 32764419 DOI: 10.3390/vaccines8030440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Guest JD, Pierce BG. Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses 2021;13:837. [PMID: 34063143 DOI: 10.3390/v13050837] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 He L, Lin X, Wang Y, Abraham C, Sou C, Ngo T, Zhang Y, Wilson IA, Zhu J. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci Adv 2021;7:eabf1591. [PMID: 33741598 DOI: 10.1126/sciadv.abf1591] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
22 Luo J, Zhang Z, Zeng Y, Dong Y, Ma L. Co-encapsulation of collagenase type I and silibinin in chondroitin sulfate coated multilayered nanoparticles for targeted treatment of liver fibrosis. Carbohydr Polym 2021;263:117964. [PMID: 33858569 DOI: 10.1016/j.carbpol.2021.117964] [Reference Citation Analysis]
23 Toth EA, Chagas A, Pierce BG, Fuerst TR. Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development. Viruses 2021;13:1027. [PMID: 34072451 DOI: 10.3390/v13061027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Yechezkel I, Law M, Tzarum N. From Structural Studies to HCV Vaccine Design. Viruses 2021;13:833. [PMID: 34064532 DOI: 10.3390/v13050833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]